Drug profile · INN
lutetium lu-177 vipivotide tetraxetan
PLUVICTO
lutetium lu-177 vipivotide tetraxetan (PLUVICTO) is a glutamate carboxypeptidase ii binding agent. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — lutetium lu-177 vipivotide tetraxetan
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
lutetium lu-177 vipivotide tetraxetan (PLUVICTO) is a glutamate carboxypeptidase ii binding agent. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Glutamate carboxypeptidase II binding agent
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Truqap gains US approval in PTEN-deficient metastatic prostate cancer
AstraZeneca’s Truqap (capivasertib) has been approved in the US with abiraterone and prednisone for PTEN-deficient metastatic prostate cancer. The move creates a first-in-class targeted option and a new catalyst to watch for BD teams, investors, and analysts.
New Radiopharmaceutical Shows Promise in Post-Pluvicto Setting, Offering Competitive Insights
A novel radiopharmaceutical is demonstrating promising results in patients who have previously been treated with Pluvicto, signaling a potential shift in the advanced prostate cancer treatment paradigm. This development presents significant competitive implications for companies like Abivax, Fulcrum, Convergent, and Vera.
Novartis Strengthens Prostate Cancer Treatment with Pluvicto
Novartis has reported stronger PSA responses with its drug Pluvicto in earlier-stage prostate cancer, indicating promising developments in oncology. This news could reshape competitive dynamics in the market.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lutetium lu-177 vipivotide tetraxetan?
lutetium lu-177 vipivotide tetraxetan (PLUVICTO) is a glutamate carboxypeptidase ii binding agent. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for lutetium lu-177 vipivotide tetraxetan?
PLUVICTO is a marketed brand name for lutetium lu-177 vipivotide tetraxetan. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lutetium lu-177 vipivotide tetraxetan?
lutetium lu-177 vipivotide tetraxetan has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.